oncodaily

Ahmet Dirican: DESTINY-Lung04 Brings HER2-Targeted Therapy Into the First-Line Setting

DESTINY-Lung04 Brings HER2-Targeted Therapy Into the First-Line Setting / Ahmet Dirican, cancer, HER2 mutant NSCLC, IASLC, ...
oncodaily

Joanna Metzner-Sadurski: Women in Medicine Recognized for Their Impact on Cancer Care

Today is National Women in Medicine Day, and this year marks the very first one! Today, we celebrate every woman across our ...
oncodailyOpinion

Martha Raymond: Honored to Be One of OncoDaily’s 100 Influential Women in Oncology 2026

Honored to Be One of OncoDaily’s 100 Influential Women in Oncology 2026 / cancer, cancer care, Martha Raymond, OncoDaily, ...
oncodailyOpinion

Sami Mansfield: GLP-1s Do the Metabolic Work, But Muscle, Mood, and Bone Need Protection

GLP-1s Do the Metabolic Work, But Muscle, Mood, and Bone Need Protection / cancer, GLP-1, OncoDaily, Oncology, Sami (Papacek) ...
oncodaily

The Big Questions in Cancer Immunotherapy: Are Personalized Cancer Vaccines Finally Ready to Deliver?

Are personalized cancer vaccines ready to transform cancer immunotherapy? Explore neoantigen vaccines, mRNA platforms, ...
oncodaily

Anemia During Cancer Treatment: Causes, Symptoms, and What Patients Should Know

Causes, Symptoms, and What Patients Should Know / anemia and chemotherapy, anemia and radiation therapy, anemia diagnosis, ...
Opinion
oncodailyOpinion

Aadel Chaudhuri: WCLC26 Highlights Liquid EcoTyper for NSCLC Response Prediction

WCLC26 Highlights Liquid EcoTyper for NSCLC Response Prediction / Aadel Chaudhuri, cancer, lung oncology, NSCLC, OncoDaily, Oncology, WCLC26 ...
oncodaily

Whole-Pelvic vs Prostate-Only Radiotherapy in High-Risk Prostate Cancer

Whole-Pelvic vs Prostate-Only Radiotherapy in High-Risk Prostate Cancer / cancer, cancer care, Cancer research, cancer ...
Opinion
oncodailyOpinion

Sam Rogers Joined LUNGevity Foundation as Chief Development Officer

Sam Rogers Joined LUNGevity Foundation as Chief Development Officer / AACR, American Association for Cancer Research, cancer, LUNGevity Foundation, OncoDaily, ...
oncodaily

HARMONi-2 Shows Overall Survival Benefit With Ivonescimab Over Pembrolizumab in First-Line PD-L1–Positive NSCLC

HARMONi-2 shows ivonescimab improved median OS to 30.8 months versus 22.6 months with pembrolizumab in first-line ...
oncodaily

ABC8 Guidelines Accepted for Publication: A More Molecular, Sequential, and Patient-Centered Framework for Advanced Breast Cancer

ABC8 Guidelines update advanced breast cancer care with new biomarker, ADC, endocrine, HER2, TNBC, exercise and ...
oncodaily

FDA Approves Taletrectinib Label Update With 49.7-Month Duration of Response in ROS1+ NSCLC

FDA Approves Taletrectinib Label Update With 49.7-Month Duration of Response in ROS1+ NSCLC / cancer, clinical trials, FDA ...